TMEM168

Across TCGA pan-cancer cohorts, TMEM168 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TMEM168 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher TMEM168 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM168 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, OV, and LUAD are the cancer types where TMEM168 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.434	.007	34	view →
OV	OS	Median	II,III,IV	0.263	0.693	.005	18	view →
LUAD	OS	Median	III,IV	0.111	0.660	<.001	18	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	9	view →
HNSC	DFS	Median	III,IV	0.150	0.682	<.001	9	view →
LIHC	DFS	Median	All	0.090	0.555	.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LGG	DFS	Median	All	0.219	0.826	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TMEM168–UCEC (DFS)

Open the UCEC breakdown →